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Abstract
Background: Natural killer (NK) cells activation has been reported to contribute to inflammation and liver injury during
hepatitis B virus (HBV) infection both in transgenic mice and in patients. However, the role of NK cells in the process of HBV-
associated hepatocellular carcinoma (HCC) development has not been addressed. Killer cell immunoglobulin-like receptors
(KIRs) are involved in regulating NK cell activation through recognition of specific human leukocyte antigen (HLA) class I
allotypes.
Methodology/Principal Findings: To investigate whether KIR and HLA genes could influence the risk of HBV-associated HCC
development, 144 HBV-infected patients with HCC and 189 well-matched HBV infectors with chronic hepatitis or cirrhosis as
non-HCC controls were enrolled in this study. The presence of 12 loci of KIR was detected individually. HLA-A, -B, -C loci were
genotyped with high-resolution. HLA-C group 1 homozygote (OR=2.02; p=0.005), HLA-Bw4-80I (OR=2.67; p=2.0E-04) and
combination of full-length form and 22 bp-deleted form of KIR2DS4 (KIR2DS4/1D) (OR=1.89; p=0.017) were found
associated with HCC incidence. When the combined effects of these three genetic factors were evaluated, more risk factors
were observed correlating with higher odds ratios for HCC incidence (P trend=7.4E-05). Because all the risk factors we
found have been reported to result in high NK cell functional potential by previous studies, our observations suggest that
NK cell activation may contribute to HBV-associated HCC development.
Conclusions/Significance: In conclusion, this study has identified significant associations that suggest an important role for
NK cells in HCC incidence in HBV-infected patients. Our study is useful for HCC surveillance and has implications for novel
personalized therapy strategy development aiming at HCC prevention in HBV-infected patients.
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Introduction
Hepatocellular carcinoma (HCC) is the fifth most common
cancer worldwide and the third most common cause of cancer
mortality. Globally, Hepatitis B virus (HBV) is the most frequent
underlying cause of HCC. In hyperendemic areas such as China
and Africa, chronic HBV infection contributes to at least 80% of
cases of HCC [1]. There is intense interest in cellular and
molecular mechanisms underlying HBV-associated HCC inci-
dence. However, due to the long duration (usually more than three
decades) from HBV infection to HCC incidence and the
complexity of carcinogenesis, mechanism underlies the HCC
development in hepatitis B patients is poorly understood.
Persistent inflammation was recognized to function as a driving
force in the journey to HCC as well as in many other cancers
[2,3]. Although accumulating reports support that NK cell
activation contribute to inflammation and liver injury during
HBV infection both in HBV transgenic mice and in HBV infected
patients [4–7], the role of NK cells in the process of HBV-
associated HCC development has not been addressed.
The activation of NK cells is dependent on the equilibrium
between the inhibitory and activating receptors, among which
immunoglobulin-like receptors (KIRs) are by far the most polymorphic.
Through recognition of specific human leukocyte antigen (HLA) class I
allotypes ligands, KIR contributes to the array of receptor–ligand
interactions that determine NK cell response to its target [8,9].
KIR function can be predicted from the length of the cytoplasmic
domain, where long (L) receptors (KIR2DL/KIR3DL) are generally
inhibitory and all short (S) receptors (KIR2DS/KIR3DS) are
activating. Two groups of human KIR haplotypes are defined
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The A haplotype carries a fixed organization of seven genes with
only one activating gene (KIR2DS4), while the B haplotype
contains varying combinations of 2DS1, 2DS2, 2DS3, 2DS4, 2DS5
and 3DS1. KIR1D is the mutant form of KIR2DS4 with a 22 bp
deletion in exon 5 which causes a frame shift, resulting in a
truncated KIR2DS4 protein that would be secreted due to the loss
of the transmembrane/cytoplasmic domains. The function of 1D is
unclear [10,11].
As one of the ligands for KIR, HLA-C molecules are classified as
either HLA-C group 1 (HLA-C1)o rHLA-C group 2 (HLA-C2) on the
basis of dimorphisms at position 80. KIR2DL1 recognizes HLA-C2
molecules that are characterized by lysine at position 80, whereas
KIR2DL2 and KIR2DL3 prefer HLA-C1 molecules contain
asparagine at this position. HLA-Bw4 allotypes are known to bind
KIR3DL1 [12,13]. The remaining HLA-B allotypes are typified by
a Bw6 motif, which is not recognized as KIR ligand. HLA-Bw4-
containing allotypes with isoluecine at position 80 (Bw4-80I)
generally bind KIR3DL1 with higher affinity than allotypes with
threonine at this position (Bw4-80T) do [8,14]. The polymor-
phisms of KIR and HLA could influence the differences in human
natural killer cell responsiveness and potency. HLA-C1/KIR2DL3
inhibited-NK cells are recognized with higher function potential
than those inhibited by HLA-C2/KIR2DL1 [9,15,16]. Individuals
carrying Bw4 have more potent NK cells than individual without
Bw4 do, because KIR3DL1+ NK subset in Bw4+ subjects exhibits
higher level of cytokine productivity and cytotoxicity in response to
various stimuli [17–19]. The ligands of activating KIRs have not
been determined.
Three virus-associated carcinomas have been reported to be
associated with KIR and HLA genes. However, opposite roles of
NK cell activation were suggested in etiology of these viral
associated cancers. In cervical neoplasia, which is caused by
human papilloma virus, and in nasopharyngeal carcinoma, which
is associated with EBV infection, KIRs or KIR/HLA compound
genotypes expected to result in an activating phenotype increase
the risk of carcinoma development, suggesting NK cell activation
may contribute to these virus-associated carcinomas [20,21]. On
the contrary, a study on HCV-associated HCC demonstrates that
a combination which conveys activating signal protected against
the development of HCC [22].
To investigate the influence of KIR and HLA genes on the risk of
HBV-associated HCC development, a case-control study was
conducted in HBV-infected patients with HCC and well-matched
HBV-infected patients without HCC as non-HCC controls. Three
genetic factors were found associated with HBV-associated HCC
incidence. Interestingly, all of these genetic risk factors have been
reported to result in high NK cell function potential by previous
studies, suggesting that NK cell activation might take part in the
process of HBV-related HCC development.
Materials and Methods
Ethics Statement
The protocol was approved by the ethics committee of the
Second Affiliated Hospital of Southeast University, and all patients
provided written, informed consent before enrollment.
Subjects
From 2005 to 2007, 333 patients with persistent HBV infection
were enrolled from the Second Affiliated Hospital of Southeast
University according to a case-control study design. Among 333
patients, 144 were diagnosed as primary HCC with liver cirrhosis
(defined as 1 or more tumoral nodules in a cirrhotic liver), 88
patients with liver cirrhosis and 101 patients with chronic hepatitis.
All diagnoses of HCC and liver cirrhosis were defined by clinical
and biological criteria and confirmed by image technologies
(computed tomography and echography).
To exclude other host risk confounders involved in HCC
development, all the patients selected here were free of other
hepatic virus co-infection, alcohol consumption, and with no sign
of autoimmune disease. HCC patients whose ages range from 20
to 65 were selected for this study. Age distribution and gender
composition were matched in the three diagnostic groups. All
patients were members of Han population and lived in the same
geographical area. KIR genotyping was accomplished in each of
the subject. Because HLA typing could not be accomplished for
some cases (because of lack of DNA), final analysis of
combinatorial KIR/HLA-C/HLA-B effects included 124 cancer
cases and 169 controls (94 with chronic hepatitis and 75 with
cirrhosis).
KIR genotyping
PCR amplification was performed with primers specific for each
locus for the presence or absence of the following activating KIR
genes: 2DS1, 2DS2, 2DS3, 2DS4 (full-length form), 1D (the 22 bp-
deletion mutant form of 2DS4), 2DS5, and 3DS1; and inhibitory
KIR genes: 2DL1, 2DL2, 2DL3, 2DL5, and 3DL1. Internal positive
control primers for fragment of framework gene KIR2DL4 were
also included in each PCR reaction. All primer sequences and
amplification conditions were as described in previous report [23].
HLA genotyping
A routine sequence-based typing method was performed.
Genomic DNA was extracted from peripheral blood mononuclear
cells by a standard salting-out method and a region including exon
2 and 3 of HLA-A, HLA-B and HLA-C loci respectively was
amplified using locus-specific primers [24]. Sequencing reactions
were performed using the BigDyeH Terminator v3.1 Cycle
Sequencing Ready Reaction Kit (Applied Biosystems) and exons
2 and 3 of each locus were sequenced in both forward and reverse
directions using a 3730XL DNA Analyzer (Applied Biosystems,
Foster City, CA). The sequences were then analyzed using online
dbMHC SBT typing tool [25].
Novel HLA class I alleles
Two novel HLA class I alleles (HLA-A*9216 and HLA-Cw*0134)
were identified in this study [26,27]. Nucleotide sequence of all the
new alleles have been submitted to the GenBank nucleotide
sequence database and is available under the accession number
EF468681 (for HLA-A*9216) and GQ365731 (for HLA-Cw*0134).
Statistical methods
Allelic frequencies were initially determined for HCC and
control groups, and the significances of genotypic and allelic
associations were determined either by Pearson’s x
2 test or by
Fisher’s exact test (when there were less than five subjects in a cell).
The level of significance of each test was adjusted for multiple
testing using the Bonferroni’s correction. Multivariate Logistic
regressions and Spearman correlation tests were conducted for
some analyses as described. HLA-C genotype frequencies were
checked for the Hardy-Weinberg equilibrium using Pearson’s x
2
test. Odds ratios (ORs) and 95% confidence intervals (CIs) were
calculated to determine the magnitude and statistical significance
of associations. All tests of statistical significance were 2-sided.
Statistical analyses were performed using SPSS software (Version
11.0 Chicago IL, SPSS Inc.).
KIR-HLA in HBV-Related HCC
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Male gender, older age (or longer duration of infection), cirrhosis,
alcohol consumption, and co-infection with HCV or HDV are
acknowledgedHCChost riskfactorsinvolved in HCCdevelopment
[1]. To exclude these risk confounders, all the patients in this study
were free of other hepatic virus co-infection, alcohol consumption,
and with no sign of autoimmune disease. HCC patients included in
this study all had liver cirrhosis. Patients with chronic hepatitis and
cirrhosis were matched with HCC patients in age and gender. Age
distribution and gender composition showed no statistical difference
both between HCC and non-HCC groups and among three
diagnostic groups (Table 1).
Combination of KIR2DS4 and 1D was associated with
disease progression towards HCC development
The frequencies of KIR genes were analyzed first. KIR2DL1
(98.5%), KIR2DL3 (98.8%) and KIR3DL1 (95.3%) were present in
nearly all individuals. The phenotype frequencies of other KIR
loci varied from 16.8% to 79.0% in the whole population of this
study. However, no significant difference on any given locus was
found between HCC and control groups (table S1).
Among the KIR genes we tested, only KIR2DS4 (full-length form)
and 1D (22bp-deleted form of KIR2DS4) have identical outer
membrane sequences. When we examined the effect of the
combination of activating KIR2DS4 and 1D, we found that the
frequency of KIR2DS4/1D was increased in HCC patients (16.9%
in non-HCC group, 27.8% in HCC group, p=0.017, OR=1.89,
95%CI=1.14–3.20). Multivariate regressionanalysis suggested that
this susceptive effect of KIR2DS4/1D (p=0.008) on HCC incidence
was independent of the influence of other activating KIRs,w h e n
KIR2DS1 (p=0.49), 2DS2 (p=0.22),2DS3 (p=0.09),2DS5 (p=0.13)
and3DS1(p=0.66)wereincludedascovariates.Furthermore,when
distribution of KIR2DS4/1D was examined among chronic
hepatitis, cirrhosis and HCC diagnostic groups, KIR2DS4/1D
frequencies in hepatitis, cirrhosis and HCC patients were observed
to be increased in turn significantly (P trend=0.004, determined by
Spearman correlation test), and this trend is dependent on both
presence of KIR2DS4 and 1D (table 2). This observation indicated
that the KIR2DS4/1D was linked with disease progression from
hepatitis via cirrhosis to HCC development.
Higher HLA-C1 copy number was associated with
increased disease progression to HCC
To test the possibility that the KIR genes are involved in risk of
HBV-associated HCC incidence, we genotyped HLA-A, -B and –C
loci, and grouped them according to KIR ligand.
As KIR ligand, HLA-C molecules are classified as either HLA-C1
or HLA-C2 on the basis of dimorphisms at position 80. HLA-C
genotype frequencies were consistent with Hardy-Weinberg
equilibrium (p=0.46). We found that genotype HLA-C1C1 was
associated with HCC incidence (p=0.005, OR=2.02, table 3).
Moreover, when the frequencies of HLA-C genotypes were
analyzed among chronic hepatitis, cirrhosis and HCC diagnostic
groups, one copy of HLA-C1 (HLA-C1C2) was found associated
with liver cirrhosis (vs chronic hepatitis; OR=2.21; p=0.01; vs
HCC; OR=2.95; p=0.001), two copies of HLA-C1 (HLA-C1C1)
were found more frequently in HCC patients than that in the
patients with liver cirrhosis (HCC vs cirrhosis OR=0.34,
p=0.001) (table S2 and figure 1). So, higher HLA-C1 copy
number was found to be associated with increased disease
progression to HCC.
HLA-Bw4-80I increased the risk of HCC occurrence
We then compared the distribution of the HLA-B ligand for KIR
between HCC and non-HCC patients. The increase of HLA-Bw4
frequency in HCC patients did not reach statistical significant level
after correction (p=0.028, OR=1.65, table 4). The HLA-Bw6
allele which was not the ligand for KIR had the same distribution
in HCC and non-HCC groups (p=0.46, OR=0.80, table 4).
HLA-Bw4-80I was recognized to bind KIR3DL1 with higher
affinity than Bw4-80T [8,14], so we analyzed the frequencies of
Bw4-containing allotypes based on their dimorphism at position
80. Bw4-80I allele was found to increase the risk of HCC
development significantly (p=0.0002, OR=2.67), while no
association was found in Bw4-80T allele (p=0.22, OR=0.74,
table 4) .Within non-HCC controls, the distribution of Bw4-80I
was comparable in chronic hepatitis patients to that in cirrhosis
patients (19.2% in chronic hepatitis patients and 13.6% in
cirrhosis patients). Multiple-variable logistic regression analysis
Table 1. Demographic and clinical features of HBV-infected patients included in the present study.
Variable Non-HCC (n=189)
HCC
(n=144) p-value
Hepatitis (n=101) Cirrhosis (n=88) Among 3 diagnostic groups HCC vs non-HCC
Age (Mean 6 SD) 43.669.7 45.368.2 45.367.2 0.20 0.33
Gender (Male %) 79 (78.2) 65 (73.9) 120 (83.3) 0.21 0.11
Other Hepatic Virus Co-infection* 0 0 0 - -
Alcohol Consumption 0 0 0 - -
*Patient sera were tested for hepatitis A virus IgM, hepatitis C virus antibody, hepatitis D virus antigen, hepatitis D virus antibody, and hepatitis E virus IgM.
doi:10.1371/journal.pone.0025682.t001
Table 2. Associations between KIR2DS4/1D with disease
progression towards HCC development.
KIR
Hepatitis
n=101
Cirrhosis
n=88
HCC
n=144 P trend
n( % ) n( % ) n( % )
KIR2DS4 76 (74.5) 69 (77.5) 121 (81.8) 0.17
KIR1D 26 (25.7) 30 (33.3) 53 (36.8) 0.19
KIR2DS42/1D2 11 (10.9) 10 (11.4) 13 (9.0) 0.60
KIR2DS42/1D+ 14 (13.9) 9 (10.2) 13 (9.0) 0.25
KIR2DS4+/1D2 64 (63.4) 49 (55.7) 78 (54.2) 0.17
KIR2DS4+/1D+ 12 (11.9) 20 (22.7) 40 (27.8) 0.004
doi:10.1371/journal.pone.0025682.t002
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(p=0.001), when Bw4-80T (p=0.57) and Bw6 (p=0.83) were
included as covariates. No interactive effect between HLA-Bw4-80I
and KIR3DL1 was observed probably due to the nearly 100%
presence of KIR3DL1 both in HCC and in non-HCC groups (table
S1).
Although some HLA-A alleles were reported as putative ligands
for KIR [28,29], no association with HCC on any HLA-A allotypes
was found (data not shown).
Combined effects of HLA-C1C1, HLA-Bw4-80I and
KIR2DS4/1D on HCC development
The combined effects of three genetic risk factors we found on
HCC development were then examined. An at least additive effect
on HCC development between HLA-C1C1 and Bw4-80I was
observed (Bw4-80I
2/HLA-C1C1
+, OR=2.00; Bw4-80I
+/HLA-
C1C1
2, OR=1.89; Bw4-80I
+/HLA-C1C1
+, OR=4.99, table S3),
which opposed to a single susceptive locus that was simply marked
by a second locus through linkage disequilibrium. Results of
multivariate regression analysis confirmed that Bw4-80I (p=0.001)
and HLA-C1C1 (p=0.007) both contributed to HCC incidence.
The combined effects among HLA-C1C1, Bw4-80I and
KIR2DS4/1D were then evaluated. A significant test for trend
determined by Spearman correlation test was observed for ORs
when more risk factors were present (P trend=7.4E-05): (a)
absence of Bw4-80I, KIR2DS4/1D and HLA-C1C1; (b) presence of
KIR2DS4/1D or Bw4-80I, absence of HLA-C1C1; (c) absence of
KIR2DS4/1D and Bw4-80I, presence of HLA-C1C1; (d) absence of
Bw4-80I, presence of KIR2DS4/1D and HLA-C1C1; (e) absence of
KIR2DS4/1D, presence of Bw4-80I and HLA-C1C1; (f) presence of
Bw4-80I, KIR2DS4/1D and HLA-C1C1 (table S3, figure 2). The
data suggest that HLA-C1C1 may be the major risk factor among
Bw4-80I, HLA-C1C1 and KIR2DS4/1D. The presence of both
Bw4-80I and KIR2DS4/1D may have stronger susceptive effect
than having only one of these risk genes when HLA-C1C1 is
present.
Discussion
To our knowledge, this is the first report to establish a close
correlation between KIR, HLA loci and HBV-associated HCC
development. Interestingly, all the risk factors we identified here
(HLA-C1C1, HLA-Bw4-80I and KIR2DS4/1D) had been reported
to result in high NK cell functional potential by previous studies.
For HLA-C1C1, direct binding assay and disease association
studies all suggest that KIR2DL3/HLA-C1 interaction results in
higher NK cell function level than other HLA-C/KIR interactions
[16]. For example, KIR2DL3/HLA-C1 has been shown to be
Figure 1. Effect of copy number of HLA-C1 on disease progression to HCC development. The frequency of HLA-C1C2 (1 copy of HLA-C1)
was increased significantly in cirrhosis patients compared to that in HCC patients (cirrhosis vs HCC: OR=2.95, p=0.001). This increase in cirrhosis
patients did not reach statistical significance level after correction when compared to that in hepatitis patients (cirrhosis vs hepatitis: OR=2.21,
p=0.01). HLA-C1C1 (2 copies of HLA-C1) was found more frequently in HCC patients than that in liver cirrhosis patients (HCC vs cirrhosis OR=0.34,
p=0.001) (table S1). * Of significant difference (p,0.006) after correction.
doi:10.1371/journal.pone.0025682.g001
Table 3. Associations between HLA-C ligands for KIR with HCC.
HLA-C genotypes Non-HCC n=180 HCC n=129 p-value OR (95% CI)
n( % ) n( % )
HLA-C1C1 108 (60.0) 97 (75.2) 0.005* 2.02 (1.23 to 3.33)
HLA-C1C2 63 (35.0) 28 (21.7) 0.011 0.58 (0.31 to 0.87)
HLA-C2C2 9 (5.0) 4 (3.1) 0.41{ 0.61 (0.18 to 2.02)
*Of significant difference (p,0.017) after correction.
{determined by Fisher’s exact test.
doi:10.1371/journal.pone.0025682.t003
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analyses also demonstrate that NK cells in HLA-C1C1 subjects
exhibit more rapid and stronger antiviral response than those in
HLA-C2C2 subjects due to different responses of HLA-C-inhibited
NK subsets [9]. In our study, KIR2DL3 (98.8%) were present in
nearly all individuals. Therefore, the presence or absence of its
HLA ligands, HLA-C1, determines the existence of KIR2DL3/HLA-
C1 interaction in any given individual. Moreover, our results
showed that more copies of HLA-C1 alleles, which resulted in
inherently more potent NK cells, were associated with disease
progression towards HCC (one copy associated with cirrhosis; two
copies associated with HCC) in HBV-infected patients (table S2
and figure 1), suggesting that NK cell activation may play a role in
HCC development.
The frequency of KIR ligand for HLA-Bw4-80I, KIR3DL1, was
also near 100% in our study (table S1), so the presence of HLA-
Bw4-80I also determines the presence of HLA-Bw4-80I/KIR3DL1
interaction in any given individual. Recent functional studies
carried out by three independent research groups reveal that
individuals carrying KIR3DL1/HLA-Bw4 receptor-ligand pairs are
of higher NK cell functional potential than Bw6/Bw6 individuals
do, because KIR3DL1+ NK subset in HLA-Bw4+ individuals are
more potent than its counterpart in Bw4- individuals [17–19]. This
is consistent with NK cell licensing [31,32]. According to licensing
theory, the recognition of self HLA class I by inhibitory KIR is
involved in the calibration of NK cell effector capacities during a
developmental stage, only NK cell subsets with inhibitory KIR that
has been recognized by self-HLA (KIR3DL1 recognized by Bw4 in
Table 4. Associations between HLA-B ligands for KIR with HCC.
HLA-B ligands for KIR Non-HCC n=181 HCC n=138 p-value OR (95% CI)
n( % ) n( % )
Bw4 86 (47.8) 83 (60.1) 0.028 1.65 (1.58 to 4.51)
Bw6 153 (85.0) 113 (81.9) 0.46 0.80 (0.44 to 1.45)
Bw4-80I 30 (16.7) 48 (34.8) 0.0002* 2.67 (1.52 to 4.52)
Bw4-80T 64 (35.6) 40 (29.0) 0.22 0.74 (0.46 to 1.19)
*Of significant difference (p,0.013) after correction.
doi:10.1371/journal.pone.0025682.t004
Figure 2. Combined effect HLA-C1C1/Bw4-80/(KIR2DS4/1D) on HCC occurrence. ORs (circle) and 95% confidence intervals (dashes) are shown
for C1C1/Bw4-80/(KIR2DS4/1D) separately. The referent groups, C1C1-/Bw4-80-/(2DS4/1D)- are those with which all other genotypically defined groups
are compared, and the OR for referent group is set at 1. We listed the various genotypes separately and ordered by increasing ORs as a means to
compare ORs of individual genotypes (table S3). Group C1C1-/Bw4-80+/(2DS4/1D)+ was not included because only 2 subjects in HCC group and 1
subject in control group carried this genotype.
doi:10.1371/journal.pone.0025682.g002
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Moreover, findings in transgenic mice support that higher ligand-
receptor interaction may affect NK licensing and result in higher
functional potential [33]. In the present study, HLA-Bw4-80I
allele, which binds KIR3DL1 with higher affinity than the whole
HLA-Bw4 allele, was observed to increase the risk of HCC
incidence, indicating that NK cell activation might be involved in
HBV-associated HCC development, which is consistent with our
findings on HLA-C locus.
The ligands of activating KIRs have not been determined. Few
data are available regarding ligands for KIR2DS4 and the
physiological role of KIR2DS4 remains unknown. Katz et al.
report that KIR2DS4 is able to interact with a non-class I MHC
protein expressed on melanoma cell lines and on a primary
melanoma to enhance NK cell activation [34]. However, they fail
to identify the ligand. We observe that the frequency of KIR2DS4 is
higher in HCC patients than in non-HCC controls, although it
does not reach statistical level (84.0% in HCC patients compared
to 76.7% in controls, p=0.099). Whether KIR2DS4 could bind
protein on HBV-infected or transformed cells needs further
investigation. KIR1D has a 22 bp deletion in exon 5 which results
in a truncated KIR2DS4 protein that would be secreted due to the
loss of the transmembrane/cytoplasmic domains. The function of
1D is unknown. Our results raise the possibility that KIR1D
molecule might be functional through interaction with the ligand
of KIR2DS4. However, the mechanism underlying this genetic
association remains unknown due to the lack of information of
ligand for KIR2DS4 and 1D.
In spite of conflicting reports, some activating KIRs are reported
to be able to bind classical HLA molecules with low affinity, such as
KIR2DS1/2DS2-HLA-C1, KIR2DS3-HLA-C2, and KIR3DS1-HLA-
Bw4. All of these putative receptor-ligand combinations were
analyzed in our study; however no significant result was observed
(data not shown).
Because most cases of HCC are detected lately and usually fatal
within a few months of diagnosis. Hepatitis B treatment and
surveillance aiming at HCC prevention is of great importance.
However, mechanism underlies the HCC development in hepatitis
B patients is poorly understood, which impedes the HCC
prevention in hepatitis B patients. Our results indicate that innate
immune response mediated by NK cell might contribute to
intrahepatic inflammation process initiated by long-term HBV
infection and eventually increase the risk of HCC development.
NK cells are highly enriched in the liver and comprise the
dominant intrahepatic lymphocyte population, yet their role in
HBV-related liver damage has not been well defined. The
CD56
dim subset expresses the majority of NK cell perforin and
granzyme, but hepatocytes are relatively resistant to these classical
cytolytic effector molecules [35]. The CD56
bright subset of NK
cells, noted to be selectively enriched in the periphery during
hepatic flares and preferentially enriched and activated in the liver,
is a potent source of cytokines such as interferon (IFN)-gamma. In
HBV transgenic mice, NK cells are reported to mediate the over-
sensitive liver injury in an IFN-gamma-dependent manner [5].
Through induction of chemokines, adhesive molecules, and
proapoptotic proteins, IFN-gamma plays an important role in
the development of hepatic inflammation and liver injury. Higher
expressions of IFN-gamma receptor on hepatocytes and stronger
IFN-gamma signaling pathway are also observed which might
account for the hypersensitivity to IFN-gamma induced hepato-
cyte injury. Additionally, NKG2D recognition of hepatocytes by
NK cells is also reported to play a critical role in oversensitive liver
injury in HBV transgenic mice [7]. In patients with chronic HBV
infection, activated NK cells are found enriched in the liver during
flares of liver inflammation, and contribute to liver inflammation
by tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL)-mediated death of hepatocytes. The authors also
demonstrate that this pathway could be further enhanced by
cytokines such as IFN-alpha and IFN-alpha/IL-8 combination,
suggesting that this NK cell-mediated liver injury can be switched
on by cytokines produced during active HBV infection [4]. Our
findings suggest that these pathways induced by NK cells may be
also involved in HCC development as in hepatic flare incidence.
Further studies on the role of NK cells during the whole course of
HBV-associated HCC development are justified in order to reduce
the intensity of the inflammatory response and risk of subsequent
HCC among hepatitis B patients.
IFN-alpha therapy has been used for decades, and has been
proven to be effective in chronic hepatitis treatment when short-
term responses, such as alanine aminotransferase level and
presence of hepatitis B e antigen are measured. Although many
studies have been conducted, the long term effects of interferon
therapy, such as prevention of incidence of cirrhosis and HCC, are
still under disputation. A recent systematic review for a National
Institutes of Health Consensus Development Conference con-
cludes that evidence is insufficient to assess treatment effect on
long-time clinical outcomes [36]. IFN is a potent NK cell activator
both in vivo and in vitro. Dunn C. and colleagues observe a
temporal correlation between flares of liver inflammation and
fluctuations in IFN-alpha in patients with chronic HBV infection.
They also report that IFN-alpha concentrations found in patients
are capable of activating NK cells to induce TRAIL-mediated
hepatocyte death in vitro [4]. Our observations indicate that over-
activation of NK cells might facilitate HBV-associated HCC
development, suggesting that the host genetic background of KIR
and HLA loci should probably be taken into consideration when
IFN therapy is applied in hepatitis B patients.
Longer duration of HBV infection is one of the important risk
factors involved in HCC development. However, because HBV
infectors can be asymptomatic for a few to more than 30 years
[37], it is almost impossible to determine the duration of HBV
infection for most HBV-related disease patients in China. It is
reported by WHO that in WHO Western Pacific Region,
persistent HBV infection mainly results from either vertical
transmission at birth or horizontal transmission in children under
5 years of age [38]. A nationwide survey conducted in 1979–1980
in China, for example, reported an hepatitis B surface antigen
seroprevalence of 8.9% in 1-4-year-olds, and changed little
thereafter [39]. Therefore, age-matching design not only excluded
one of the major risk confounders of HCC occurrence, but also
made all three diagnostic groups comparable in terms of
approximate duration of HBV infection. Although the design of
age and sex-matching as well as other entry criteria (such as free of
other hepatic virus infection and alcohol consumption) restricted
our patient selection and led to relative small sample size, the
strict-match design enhanced comparability of our case-control
study and made our results more reliable.
A recent genome-wide association study (GWAS) identified
1p36.22 as a new susceptibility locus for HBV-related HCC [40].
In this study, Zhang and colleagues genotyped 440,794 SNPs in
HCC patients and non-HCC controls lived in Guangxi province.
Then they examined the top 45 significantly associated SNPs
detected by GWAS in other independent samples and confirmed
one SNP. No SNP within HLA or KIR region was found associated
with HCC incidence in Zhang’s study. We do not think it is in
conflict with results of our observation. One of major reasons is
that GWAS which is based on testing SNPs one by one can not
perceive risk factors when the effect depends on the co-existence of
KIR-HLA in HBV-Related HCC
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activation depends on each other through ligand-receptor
interaction. In our study, HLA-C1C1 and HLA-Bw4-80I could be
detected as risk factors probably due to the nearly 100% presence
of their KIR receptors in our population (table S1). However, KIR
frequencies have been reported to be varied with geographical
position and ethnic groups throughout China. For example, in
Guangdong province, which is adjacent to Guangxi province
where the GWAS is conducted, only 58% of the population
possess KIR2DL3 [41]. For KIR2DS4/1D, the susceptive effect
depends on the presence of both KIR2DS4 and 1D as shown in
table 2, and this effect could not be detected by GWAS neither.
Hence, our association study, which investigated the combined
effects of functional related polymorphic loci, could discover risk
factors that could not be detected by GWAS.
Although the exact role of HBV genotype in hepatocarcino-
genesis remains to be clarified, some genotypes are thought to
increase the risk of HCC, such as HBV genotype C in Asian
cohorts [42] or genotype F in other populations [43]. One
limitation of our study is lack of information of HBV genotypes in
the patients. Another limitation is that KIR allele polymorphisms
were not analyzed in this study, since KIR polymorphisms,
especially KIR3DL1 polymorphisms had been reported to affect
NK cell inhibition by HLA ligand [44]. Large prospective studies
are needed to confirm the results of our study.
In conclusion, the results of the current study showed that HBV-
infected patients with certain KIR and HLA genotypes were more
likely to develop liver cancer, providing genetic evidence of that
over-activation of NK cell might contribute to hepatitis B
progressing to HCC development. Our study is useful for HCC
surveillance, and has implication for personalized hepatitis B
treatment aiming at HCC prevention.
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